2-methoxyestradiol has been researched along with Bone Loss, Perimenopausal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chambon, P; Fujie, A; Hao, W; Johnson, RS; Kanagawa, H; Kato, S; Katsuyama, E; Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Miyauchi, Y; Mori, T; Morioka, H; Sato, Y; Tando, T; Toyama, Y; Yoshida, S | 1 |
| Andréasson, E; Carlsten, H; Islander, U; Karlsson, A; Ohlsson, C; Stubelius, A; Tivesten, A | 1 |
2 other study(ies) available for 2-methoxyestradiol and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis.
Topics: 2-Methoxyestradiol; Administration, Oral; Animals; Cells, Cultured; Crosses, Genetic; Enzyme-Linked Immunosorbent Assay; Estradiol; Estrogens; Female; Genotype; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Immunohistochemistry; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Knockout; Osteoclasts; Osteoporosis, Postmenopausal; Polymerase Chain Reaction | 2013 |
Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis.
Topics: 2-Methoxyestradiol; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Estradiol; Female; Humans; Mice; Mice, Inbred DBA; Osteoporosis, Postmenopausal; Ovariectomy | 2011 |